3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition.
Toxicology Letters March 22, 2011 DOI: 10.1016/j.toxlet.2011.03.007 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | MDMA |
| Key points | Reports that MDMA inhibits CYP3A through both PXR activation inhibition and catalytic enzyme inhibition, indicating a potential for drug-drug interactions. |
Abstract
3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition.
Citations in the library
Cited by 2
- Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model. Daru June 28, 2017
- Induction of glutathione synthesis and conjugation by 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-dihydroxymethamphetamine (HHMA) in human and rat liver cells, including the protective role of some antioxidants. Toxicology November 18, 2011
Cites 6
- Human Pharmacology of MDMA Therapeutic Drug Monitoring March 19, 2004
- Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humans British Journal of Clinical Pharmacology February 1, 2000
- Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity. Drug Metabolism and Disposition July 2010
- Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship. Chemical Research in Toxicology October 2006
- Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. Journal of Pharmacology and Experimental Therapeutics April 2005
and 1 more in the library